Targeted core-shell nanoparticles for precise CTCF gene insert in treatment of metastatic breast cancer.

Bioact Mater

State Key Laboratory of Natural and Biomimetic Drugs, Beijing Key Laboratory of Molecular Pharmaceutics and New Drug Delivery Systems, And School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China.

Published: May 2022

Clustered regularly interspaced short palindromic repeats (CRISPR) technology emerges a remarkable potential for cure of refractory cancer like metastatic breast cancer. However, how to efficiently deliver the CRISPR system with non-viral carrier remains a major issue to be solved. Here, we report a kind of targeted core-shell nanoparticles (NPs) carrying dual plasmids (pHR-pCas9) for precise CCCTC-binding factor (CTCF) gene insert to circumvent metastatic breast cancer. The targeted core-shell NPs carrying pHR-pCas9 can accomplish γGTP-mediated cellular uptake and endosomal escape, facilitate the precise insert and stable expression of CTCF gene, inhibit the migration, metastasis, and colonization of metastatic breast cancer cells. Besides, the finding further reveals that the inhibitory mechanism of metastasis could be associated with up-regulating CTCF protein, followed by down-regulating stomatin (STOM) protein. The study offers a universal nanostrategy enabling the robust non-viral delivery of gene-editing system for treatment of severe illness.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8661137PMC
http://dx.doi.org/10.1016/j.bioactmat.2021.10.007DOI Listing

Publication Analysis

Top Keywords

metastatic breast
16
breast cancer
16
targeted core-shell
12
ctcf gene
12
core-shell nanoparticles
8
gene insert
8
nps carrying
8
cancer
5
nanoparticles precise
4
ctcf
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!